Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;21(9):2407-2409.e2.
doi: 10.1016/j.cgh.2022.03.035. Epub 2022 Apr 2.

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Nathaniel A Cohen  1 , David Choi  1 , Tenzin Choden  1 , Noa Krugliak Cleveland  1 , Russell D Cohen  1 , David T Rubin  2
Affiliations

Ozanimod in the Treatment of Ulcerative Colitis: Initial Real-World Data From a Large Tertiary Center

Nathaniel A Cohen et al. Clin Gastroenterol Hepatol. 2023 Aug.

Abstract

Ulcerative colitis (UC) is a chronic inflammatory condition affecting the colon and rectum. Long-term therapy is generally required to achieve and maintain disease control.1 In May 2021 the US Food and Drug Administration approved the use of ozanimod in patients with moderate to severe UC. We describe the first report of the use of ozanimod in real-world clinical practice.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
Survival curves of the rates of continued ozanimod use in patients with A) any prior advanced therapy (biologic or small molecule) exposure before ozanimod, B) mesalamine only exposure before ozanimod, C) any previous vedolizumab exposure before ozanimod, and D) vedolizumab use immediately proximal to ozanimod use.
See this image and copyright information in PMC

References

    1. Rubin DT et al. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384–413. doi:10.14309/AJG.0000000000000152 - DOI - PubMed
    1. Fronza M et al. An overview of the efficacy and safety of ozanimod for the treatment of relapsing multiple sclerosis. Drug Des Devel Ther. 2021;15:1993–2004. doi:10.2147/DDDT.S240861 - DOI - PMC - PubMed
    1. Sandborn WJ et al. Ozanimod as Induction and Maintenance Therapy for Ulcerative Colitis. N Engl J Med. 2021;385(14):1280–1291. doi:10.1056/nejmoa2033617 - DOI - PubMed

Publication types

LinkOut - more resources